InskoBi's APUS Completes NYSE Listing, Raises $13.5 Million Through IPO

KOSPI-listed InskoBi announced that its subsidiary, Apimeds Pharmaceuticals US Inc. (hereinafter "APUS"), has completed its listing on the NYSE American, a market under the New York Stock Exchange (NYSE), and began trading at 10:30 a.m. (EDT) on September 9, 2025, local time.

Through this IPO, APUS offered a total of 3,375,000 shares, raising $13.5 million (approximately 19 billion KRW). This successful listing follows the initiation of a confidential S-1 registration in January of last year and approximately 16 months of SEC review and disclosure procedures.

Based on the funds secured, APUS officially announced the initiation of a Phase 3 clinical trial with the FDA for multiple sclerosis (MS) indications of its main pipeline, "Apitox." The company is currently in the final stages of contract negotiations with a global contract research organization (CRO), while also proceeding with clinical trial design and site selection. In addition, APUS is internally reviewing the expansion of its clinical pipeline in the United States to include additional indications such as rheumatoid arthritis and psoriasis.

An InskoBi representative stated, "APUS shares are listed under the ticker symbol 'APUS' and can be traded through the overseas stock menu of HTS and MTS platforms at all Korean securities firms," emphasizing, "This will not only enhance credibility in the global bio market but also significantly expand investment accessibility for Korean investors."

Even after the listing of APUS, InskoBi will retain approximately 60% ownership of APUS, maintaining its position as the largest shareholder and continuing to be deeply involved in management and strategic decision-making.

InskoBi stated, "The listing of APUS is significant not only as a means of capital raising but also as a foundation for its leap forward as a global bio company," adding, "We will actively manage market-making and the liquidity of circulating shares not only through our U.S. underwriters but also at the headquarters level."

Meanwhile, InskoBi and APUS plan to focus all efforts on establishing a foundation for sustainable growth, including U.S. FDA Phase 3 clinical trials, expanded overseas IR, increased institutional partnerships, and the addition of new indications.